Merit medical reports fourth quarter and full year 2024 results and issues fiscal year 2025 guidance

Fourth quarter highlights† reported revenue of $355.2 million, up 9.4% constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectively gaap operating margin of 10.3%, compared to 10.4% in prior year period non-gaap operating margin* of 19.6%, compared to 16.6% in prior year period gaap eps $0.46, down 2.6%, non-gaap eps* $0.93, up 25.8%, and free cash flow* generation of $65.3 million, up 18.4% fiscal year 2024 highlights† reported revenue of $1.357 billion, up 7.9% constant currency revenue* and constant currency revenue, organic* up 8.5% and up 6.0%, respectively gaap operating margin of 11.5 %, compared to 9.9% in prior year non-gaap operating margin* of 19.0%, compared to 17.2% in prior year gaap eps $2.03, up 25.3%, non-gaap eps* $3.46, up 21.3%, and free cash flow* generation of $185.7 million, up 67.5% fourth quarter business developments completed the acquisition of lead management portfolio of medical devices and certain related assets from cook medical holdings, llc announced fda premarket approval of the wrapsody® cell-impermeable endoprosthesis device, which is intended to extend long-term vessel patency in dialysis patients substantially completed integration of the production, distribution and sale of the esophyx® z+ device previously acquired from endogastric solutions, inc. fiscal year 2025 guidance revenue of $1.470 billion to $1.490 billion, up 8% - 10% year-over-year non-gaap eps of $3.58 to $3.70, up 4% - 7% year-over-year † comparisons noted in the bullet points are calculated for the current quarter compared with the fourth quarter of 2023 or for the current year compared with fiscal year 2023, as applicable, unless otherwise specified. amounts in this release are rounded while percentages are calculated from the underlying amounts.
MMSI Ratings Summary
MMSI Quant Ranking